EDIT - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to Editas Medicine’s Fourth Quarter and Full Year 2019 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the Company’s request.

I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at Editas Medicine.

Mark Mullikin

operator. you, Thank and year everyone, our quarter fourth Good conference welcome call. full XXXX and afternoon, to Shortly market for our financial and after release year results press the full and closed, we corporate updates XXXX. the quarter a fourth issued providing available today’s section & website two be our completion. its the hours Investors A replay after will on of approximately call Media of After our for call Q&A. prepared remarks, the we will open

statements materially factors, our remarks quarterly report differ about as and Reform various important including statements results reminder, Private that those purposes forward-looking the is prospects future forward-looking a on during the Form discussed call most recent we XX-K, may safe Risk by file those As this of Act SEC. from which with the in plans Company’s expectations, the constitute under these section Actual various a result harbor for of make of provisions on XXXX. Litigation of the indicated Factors Securities

forward-looking our Except views as representing represent any we statements, or upon as any of revise to In our views obligation required if relied any of date. by any subsequent only today should even specifically law, be our views addition, update statements change. as and not disclaim forward-looking as

the I Cindy Collins. our Now, turn call Chief will to over Executive Officer,

Cindy Collins

the you, Good quarter full fourth for our and thank afternoon update you and corporate everyone XXXX. Thank call Mark. for for joining us year

Tim the Vice members new Affairs. Medical In our Scientific executive addition Officer, Michelle Officer; Chief to Senior our President of including Financial Editas Albright, Officer, Judith Chief our Corporate Mark, several by our and Charlie joined team, of Abrams, Chief I’m Hunt, Robertson,

today’s and and a serious look at point differentiated, call, ahead XXXX Medicine, have we developing are some to what On the review work of we transformational year, achieved diseases medicines point an beyond. range of across past We the patients. them over then seeing Editas will in at a of nearing exciting

medicine with accomplishments for our with best-in-class ever of of with collaboration in an initiated start over So, CRISPR let’s We LCAXX. IND-enabling the first of EDIT-XXX the Allergan trial vivo clinical year. some started of past We patients studies treatment to in with part Squibb, medicines cell medicine developing focus for for cell collaboration disease. a alpha-beta Celgene, on as amended cancer. We sickle Bristol-Myers now our for T EDIT-XXX of potentially the engineered

We are blood with treating leader cancers. excited continue to our work in the

With we regained medicine payment the cell a right $XX million to received engineered gamma oncology. amendment, cash and T develop in

development research to our iPSC-derived medicines Chief as Michelle We Abrams using our Senior President our enabled NK Therapeutics, BlueRock to expansion are added develop pleased of leadership with our donor from Medical technology and I We outstanding Sandhill Therapeutics. our tumors in cell NK join am And case we call Judith Officer; the the Vice Financial Harry of me have Officer; and medicines as with Michelle Chief cancer all collaboration. allogeneic Robertson Judith accelerated appointments executive of cell technology newly cell today. on advancing from Gill and as for Operations. we a engineered solid healthy formed efforts medicines through for

autosomal nominate cell tumors, treat medicine tumors. solid the the in for collaboration coming dominant initiate an in an sickle first for the of for treat our EDIT-XXX Brilliance we X of IND to medicine candidate Phase engineered vivo cell give preclinical and donor trial to data patients IND-enabling EDIT-XXX iPSC-derived of to allogeneic pigmentosa development treatment us solid healthy file in the proof-of-concept year. present finally Allergan. NK cell a into studies dosing candidate for RPX, These an or disease, NK in retinitis XXXX, partner accomplishments announce to quarter plan We momentum X/X plan In with for

Abrams, to on Judith call the turn trial our EDIT-XXX. me X/X clinical Phase let Now, update to of Medical you Officer, over Chief our

Judith Abrams

Thanks, you on of join call today. Cindy. all It’s the pleasure my to

X/X and with the the Brilliance patient last announcement the we expect study for first opened that in this patients recent months we year in LCAXX first mentioned, activity to quarter dosing for Cindy on year. As Phase of has enrollment. accelerated Enrollment

a progress clinic, dose the devastating durably LCAXX. mark milestone building As CRISPR Brilliance will senior promise research as share delivering continues a clinical I’m patient our our such clinical trial that reminder, leadership significant we to in medicine the first are as pleased to to toward of the the pipeline also on to treat organization. in potential our diseases

to our Albright, discuss I’ll now our the call Chief to Officer, pipeline. Scientific broader Charlie turn over

Charlie Albright

Judith, and us all joining for Thank thank you, call. you on the

are our formed support vivo IND-enabling aureus advancement studies a in EDIT-XXX the EDIT-XXX USHXA, Preclinical study, CasX XA program photoreceptors EDIT-XXX in potential delivered XXXX. benefit. EDIT-XXX EDIT-XXX. and disease that transcriptional LCAXX, licensing does since EDIT-XXX levels, AAVX same the as leads and retinal to At therapeutic or next with phenotypic blindness. is data level, delivery package inherited for on to the the identical development Based strategic an editing promoter USHXA. enzyme, vector, of our EDIT-XXX, for and staph we Syndrome Like product demonstrated EDIT-XXX consistent data, affects is have restoration we alliance the as treatment that levels for of Following is that photoreceptor-specific ocular Usher and part proprietary in we to nearly mRNA uses of and Allergan these

in later candidate AskBio in disease, pipeline leveraged and research present in aureus Our staph our vivo other development particular, are being in we delivery AAV diseases learnings with year. editing vivo studies for to retinal and our of medicine RPX, in collaboration expanded IND-enabling initial data at hope neurologic this aimed is EDIT-XXX into used inherited medicines, where CasX with for EDIT-XXX declare We’ve plan this year. to another

medicines programs. cell engineered our to Transitioning

developing a for beta-thalassemia. are disease EDIT-XXX best-in-class medicine We cell as and sickle potential

and cells. and is CasXX Our in a the CasXXa stem the fetal to to CpfX. beta-globin enzyme hematopoietic Editas to program induce uses edit as promoter known HBGX/X proprietary locus hemoglobin previously

competitors our the program, enhancer, from our or edit BCLXXA differentiated with who gene unfamiliar is use locus either therapy. approach those For

human our the the genetic at genomic data these shared as Hematology is latest region risk the EDIT-XXX enhancer approach found support American important human This validation. BCLXXA December. reduce and edits genetic Society efficacy increase In safety. in not of where mutations contrast, hemoglobin. We to the data are fetal at human of Conference does have

data does For EDIT-XXX durable, cell of is fetal impact shows hematopoietic high blood not preclinical hemoglobin HBG stem levels cells n editing lineage. and induces negatively

for of filing IND EDIT-XXX cell by for sickle plan year treatment patients with disease the end. We

major cancer. for our focus treat programs to is other The cell engineered medicines

cell believe medicine alpha-beta in where effective. leader potential has to blood we T cancers alpha-beta cancer be treating We’re T collaboration the Squibb, the engineered cell developing medicines for an with in particularly Bristol-Myers

and tumors. wholly-owned we advancing healthy donor NK gamma-delta solid cell addition, immune In treat our tumors. begin T are by cells solid plan cells, treat to to IND-enabling studies an to including medicine editing NK We innate mid-year edited programs for

We recently method. Sandhill work announced accelerate manufacturing our medicines. Therapeutics and to with proprietary healthy Sandhill expansion donor processes, brings infrastructure established

gene In the Bayer, cell editing together cell we parallel two for iNK to brings solid therapies. are engineered cells cells. can form healthy of the Combining technologies BlueRock great advancing and partnership now made or NK iPSC-derived cells part tumors. CRISPR differentiating editing, progress with platforms Therapeutics, we program, iPSC iPSCs donor with and In of that revolutionize iNK as medicines engineered

progress the in look you on this near about and our to potential updating forward excited future. We’re

Chief newly to Robertson. Michelle the Now, I’ll over turn our Officer, call appointed Financial

Michelle Robertson

most that, Thanks, join years, biotech financial and more number in introduce XX all present Charlie. CFO recently Momenta than for leadership you Pharmaceuticals today a finance working at in prior the Baxalta of the I’m to latest I’ve please Genzyme, and roles Ironwood. the of to industry to Company’s and been myself results. in as

of through much patients medicine that opportunity working need. this for develop make potential transformative of to to as patients. were the the drawer. on differentiated To company possibilities in role, diseases from the are difference It’s us what future Editas the Editas infinite of big we to as companies a think me In company is hard unmet for other develops another help with to the medicines with

the Now numbers. turning to

quarter year and in full results We have issued the XXXX our press the earlier summarized that release financial for we today. fourth

XXXX as equivalents from Our XXXX, of XXXX. XX, cash, $XX to increased million cash million XX, marketable million in December $XXX December and of $XXX as securities

of operating of expenses $XXX and million uses $XXX expenditures cash cash capital million. $X and totaled of included million Our

the XX%, increasing the Over approximately XXX at the The course XXX advancement growth to in by and platform. pipeline of year, maturation the size time of we organization our of in spending full expansion of XXXX from of and end employees XXXX. was the our our grew the

driver to expect to We be spending in of continue the this primary XXXX. growth

in proceeds payments Our $XXX $XX $XX million stock sources XXXX business exercises. million option development primarily million and million $XXX and in cash through insurance, equity raised partners, milestone totaled from our of of from consisted

runway least Editas of financial business. fund to position the is XX with in strong a at months

hand And with that, it I’ll to back Cindy.

Cindy Collins

Thank you, Michelle.

strong to of year. and Editas exciting It the in leadership guide next confident we months as embark for Company an has we We look busy few phase are the biotech become stage our been a toward clinical growth. a on past and our as time coming

long-term out We of our organization. that confident the strength in have will support leadership filled team growth the executive and are

unparalleled the of of transformational unmet discovery with pipeline our coupled for programs best-in-class represent medicines from a Our need. diseases research lab

your lives. promise to beyond We as on transform all we to look are you will of for to and hold interest and see support. the We what XXXX patients’ deliver of thank eager CRISPR

that, for With we open the call Q&A. Operator? up will

Operator

of Raymond [Operator Instructions] comes from And the Seedhouse our James. with Steve first question line

Steve Seedhouse

that the on well. would conditions set, or at iterations included variant so or My guide complexation ASH, question the enzyme is the the you electroporation the EDIT-XXX, protocol, as and for nice conditions and like presented whether data sort it the of the optimizing was data

other pieces there’s first there. targeting aside we guys editing in been of to I just So a the you you down of improvement for if the and approaches, different the to lot locus targeting? characterize, done, I’m there’s or RNP to some basically conditions, complexation if a fact believe electroporation -- over an pitch already does you could are gene set that what’s different you’re understand or a what moving curious locus and novel are the wanted that the basically the like movers so optimized are And extent the EDIT-XXX boil best-in-class

Charlie Albright

we a Charlie. believe couple secondly, of Steve, with comes One, a induction; believe BCLXXA it from comes editing and hemoglobin The as best-in-class carry things. we the superior have potential we this levels in we bag don’t fetal of enhancer. is

you And even models out in we preclinical that enhancer. consequences. because BCLXXA, causes appreciate, our with you dire knock have issues BCLXXA found As can’t the

So, site, hemoglobin of in locus. the we’ve at front after gone it a

we we then induction, hemoglobin would So, we we and sites do entire genetically combinations the that locus, thought for most found look could scanned we enzyme fetal know the And hemoglobin it’s validated. that. get the

anytime edits did lot non-productive as are appreciate, and with CasX. So with cut. yielded being found CasXXa you there And it at the than we at cutting productive we you site productive both that cutting a more

a CasXXa. But we variety to optimize product, to of did we make the And that mentioned needed cutting work with with as as you methods. that

the We of increased to the have optimized enzyme activity, we and that guide electroporation CasXXa the variations of that have editing, we’ve increase variants the conditions. has and do ability

into the And things so, went all product. building of those

Steve Seedhouse

differences thought That the not, -- see quite are on if in and ongoing is helps are rodent versus studies testing that approaching the to beta-globin or just also between EDIT-XXX, ask wanted studies? generation it IND, models bit. factors that comprise understand the gating the the the worth is to targeting a approaches? I an And if of primates, biology remain events sufficient sequence any process sort to in primate of first it

Charlie Albright

We don’t studies. ongoing primate have any

redesign primate So, going of to be studies, predictive more be have actually rodent the entire clear to to the other genome. the primate Because than yet or studies do not. studies are has whether the kinds it It’s product. primate not to you

to this feel get that we thing do clinic is class possible, to actually point, this into medicine. determines the certainly clinical course as at so, the with of as And the quickly because all data it’s the like

Steve Seedhouse

the some out curious, if would one. up on breaks in just and quarter. quick could I go operating like on shed was Thanks basis? what It last taking forward that forward a how light into you just just the went expenses carry looks next for questions. And year considerably

Michelle Robertson

in advance, to expect The invest, continue as Sure. we continue they we’ll the And into especially to programs that clinic. XXXX. go

Operator

next BTIG. And question with Murphy Amanda the of our line from comes

Your line is open. now

Amanda Murphy

out a I I with had oncology around I now business. BMS the more And guess, to few start just questions relationship. wanted the,

obviously specifically overall, talked about competition there’s share you that’s kind You not a there and sure curious just cells allogeneic of terms in progressing. But of of can I’m there. lot how what

of number in a for that and They on program. years. clearly interested you working are been You’ve re-upped with the

data those in-house if wondering, you’re on coming programs just ton alpha-beta progress? this there’s I let’s that how shift And start on But a of on. to So might programs with after thoughts want year, to that the -- we there can. your all what working

Charlie Albright

they’re they Okay. leading. and leadership. We from the maintain for it’s Yes, be we going on a CDXX BCMA Hi, -- did say there’s leaders way I hematologic can’t back indications. that chance I want -- to programs a think, are what’s Charlie. share to those And going industry of more can medicines We there. going are light good details the generic to Amanda, with their in BMS. that perspective, cell-based programs they’re think We re-up in up that and a

of we’re through of lot And they’re to think I going what detailed able liberty a the use it’s been And some products safe cells. years edits to to T those but in so, about of same the to are. we’re targets, types disclose disclosed want at assume not we’ve make to data the

Amanda Murphy

Yes, when Sandhill think you now fair than a about kind you’ve with what of building challenges cells I the is obviously And using been of mean, and cells with done understanding sizeable expansion, out enough. NK NK technology. that my a one the quite of is expansion portfolio you’ve key then,

talked then, got working as I Sandhill, of you’ve you’ve about, agreement, so And gamma-delta BlueRock. BMS the cells. obviously part think back And with

back have get sort companies, perspective, discussed time a other innate from you’re of taking you a level some think a high evolving level how cetera. see as effector been and else over talked do as regs about from also to just of view interesting? T a a how the cells So, pipeline would do target, about you And love you thinking solid tumor backbones. but of kind I just high what is this et by think, step

get there. to So perspective wanted

Charlie Albright

a take We’ll that. stab Yes. at

system. immune innate the like we So,

And so, back we come the feel place minute. a to I’ll like NK start. And cells gamma-delta in to are

of cells cytotoxicity things that know host. part Herceptin among are part we and or a antibody mechanism So, directed propensity for your we therapeutic low others. the the also of of antibodies, is such And Erbitux cells know graft NK NK versus have ADCC, as which cellular very that

come already So, medicines, in comes when it to a allogeneic good place. making truly they

out the worked is that know making further to iPSC-derived point. we And NKs well path reasonably at this

NK to of We in all that that together there go the as cells solid we’ve via T do which are So, indications we taken are and unmet the the things after any they’re are need, leading solid And major us those is cells, as tumors. well. of about editing. exhausted think that things can the tumor gene exhausted

them targeting, the among CDXX we tumor increase so, things make better, overcome the pathway to want do IL-XX, and to the microenvironment make And is allogeneic. sensitivity truly

but much lies be iPSC the space platform, not editing, are the engineered in, there healthy do highly be with with ability So, and are ultimately to all is we of think of needed those advantage are you medicines, only in going gene they possible which number limited those of do successful donor become can making things to the your to this better, ease cells, enabled. construct the

we’ve So combination we built years with of iPSC got BlueRock is the of from the with by platform the are that lines we’ve jump-start over a platform an the editing cell in platform, industrializing getting five last process Therapeutics. which a

get to Did want where you that go? you

Amanda Murphy

Yes.

think that questions -- seems I just there, that NK is talking way also using to be with about but a expansion it’s I asked many something cells. think I challenge in too

more get and perspective also to there then delta. a gamma little wanted So

Charlie Albright

Yes.

of it’s healthy a for it more than of what issue an where iPSC-derived a we part that’s for is donors just grow get can cells you whole -- So lot.

And so, for Sandhill of what plate to that’s the brings part us.

help So -- enable and to going program. healthy our donor that’s

begin edits will learn in but We what solid let about of different these tumors. context us do the

Amanda Murphy

yes. then it’s to say So -- fair

Go sorry. I’m ahead. Go Sorry. ahead.

Charlie Albright

among between reasons of it’s an part another immune worked are and are your less solid of as that interesting relationship than biology see control Gamma-delta gamma delta among tumor NK system. are. is the less best area cells, cells the things they’re remain is out correlated growth. the in tumor gamma But and you in tumor well cells the of that of interesting the the control solid delta the the they Obviously, innate number

the it’s So, to we’re interesting you’ll coming that ability now more area. area, an glad that have to in work the about in And hear months.

Amanda Murphy

really tackle tumor engineered using say different using edited So to approaches effector you’re fair cells. solid to

a… So about the right think way that -- to as is it that

Charlie Albright

natural trying we’re cells trying better. them and we’re Yes. restore to say, -- and and of would I and them the take them to further properties NK make make And --

told antibody-directed so, ADCC. NK And you, cellular participate cells, cytotoxicity as I in or

We also MHC. that recognize lacking are cells

T And so, express antigens. cell thereby don’t

one the the cell to T PD-X is so, And mechanisms major of resistance inhibitor loss of antigen expression.

you that had therapeutic you specifically if PD-X. a those So target have nice add the could on a cells,

Operator

Morgan from Matthew Thank our Stanley. next question you. the line of Harrison comes with And

line now Your open. is

Thomas Lavery

Matthew’s I EDIT-XXX. Allergan, Hi, what Lavery This opt-in, Thank would plans they partner, decide on don’t When guys. you. a is team. to a question your pursue next trial steps? Thomas be alone? from And to about is need have your if

Charlie Albright

Sure.

and candidate criteria. essentially the medicine that with and at targets then package, we go agree be the as that on development a criteria So we that, stage. deliver we would known is the what Allergan then we is the away, option fulfills started deal develop structured we And before a way the program the option

And And opt-in. then we opt-in, to for So then not and us if period a to product time to the study. to and in decide We or own. decide then window the has back they about them them. it’s and a make ready of to co-opt-in to after whether the Allergan did right package that -- decision have with on we develop evaluate they not have a co-develop tox IND-enabling And medicine opt-in for where it our we LCAXX. comes with that that,

Operator

Thank you.

the with Our question Gena Wang Barclays. of comes next from line

now Your line is open.

Unidentified Analyst

taking for you [ph] Thank Gena. Hi. for June question. is This my

released? my us of will us color So first when clinical the And about really about then you first about a, give LCAXX. can the first. question guidance give of looking the be on to bit move all, Thank data some is a the Could to also, initial you be of biomarkers range dose kind dose? would to that your I would what to you’re also, decide you will follow-up that. pay? going whether have you have you And higher after help a you. for That’s

Cindy Collins

Okay. Thank you for the question.

I’ll So bit little and range. overall it is ask the dose well. to and part start going more Charlie a with very about first talk the But, biomarkers of trial

screening not will actively disclosed in time. are We patients point data and announce we this at when have

As made we earlier, this I to first we sharing quarter, commitment dosing but think not data. do Charlie, we any mentioned of expect about announce around want you have patient the when might to...

Charlie Albright

dose, on we and by used of trial. to dose, our have it’s span a and -- therapy studies, efficacious. pick dose be do And the mid you realistic low, a they based a gene preclinical the chance dose and lowest The narrow range, a and showing in the has that’s doses based for preclinical to The that efficacy have efficacy relatively LUXTURNA a Spark we dose are -- low they was trials, it high so, on found studies. the

at of looking clinical a We’re range outcomes.

as as that and and the physiologic as how them structural including and well consideration, advance all ERG well safety the we’ll are program. as to their take markers, into as -- visual decide acuity, we clinical, electric and data of OCT, Some

Unidentified Analyst

Great.

patient to time to to the Just information the lowest after your whether that going you enough how decide you two time dosing following between have wait on in to that, higher doses? will -- What’s move of the on think before dose? dose generally you’re long week

Cindy Collins

be of duration. six So, can cohort -- we review weeks in approximately have a period conclusion program safety that review the be And to at one.

Unidentified Analyst

Okay.

preclinical about have advantages another have. So your ASH about question Obviously, from data disease. have you elaborated also you sickle I the cell and you the

understanding, be program be your What move myself will best-in-class of something for it just give you benchmark of confident looking percentage as are think like will for editing kind gene you efficacy forward? level what suggested? of or to better So you you the

Charlie Albright

gene I not much fetal it’s just induction. editing, think it’s so hemoglobin of

going then looking are technical the for percent obviously, clinical would optimize outcomes. hemoglobin levels based on we’re, be and to of So predictive features. really the we’re fetal editing, that of But what

Operator

And you. from next Thank with our Company. the line Joe of Thome question comes Cowen &

open. now is line Your

Joe Thome

and thank taking there, my questions. Hey for you

On expect first the before been let you kind that the needs happen the EDIT-XXX patient just study, what still toward year, maybe And forward in year-end? the And you’ll us two if study kind to has then is have you end scheduled? dosed? -- surgery know cohorts do first patient can of by of patients looking dosed that of the of that

Cindy Collins

Yes. for Thank question. the you

So, as I going well. very is trial mentioned, the

We are actively screening patients.

screening patients from heard more complicated our working with getting contact we us of Allergan previously, has and like patients. screen to types are and continue you As bit but things members, collaboratively to that, daily trials other with the just enrollment than caregivers, little in family very lined the been partner, a up

cohorts still very tracking do had So I We we’re the and said toward that first we two earlier good treat that. year-end hope to where by feel we are. both about

Joe Thome

have kind and partner programs. a combine you of Obviously, When you’re have do new you decide one more a program strengths looking their going just partnered their how I on versus that expertise of of then important and And is lend broad into great. kind Okay, a alone? can it on and strategy. area? to therapeutic at more a guess, collaborative lot

Cindy Collins

taken obviously, each in We’ve isolation. those, one

We are so, role co-developing The that with Allergan, there. a have unique extreme -- co-commercializing was our Celgene-Juno per was But a partnership And partners bit have it collaboration. and in formerly BMS, little we now as we different therapies. development where potential facilitate cocoing we purposeful some was the capabilities such to weren’t where technology were deals quickly. that more getting really access done important we or recent to and degree, terms of going and BlueRock, AskBio, some much we’ve in thought With and either programs more to were that the getting of se. and the up running those Sandhill products

Joe Thome

and again much so progress. on congrats you Thank the Great.

Cindy Collins

Thank you.

Operator

Thank question with from line our Geulah you. And Chardan. the of next comes Livshits

line now Your is open.

Geulah Livshits

taking thanks guys, Hey. and afternoon, questions. Good my for

prior follow-up questions about EDIT-XXX. to So, on that

mentioned So been [Indiscernible] the is to the same think was factors third be expected the had I that the have patients patient still it identified. that of stick couple timing I at And And is some quarter a dosed? that dosing. results the then one around of to of follow-ups.

Cindy Collins

So, I’m not statement first as sure being are, se, we said, the screening I recall patient but I specifically actively per about a identified patients.

patients cohort first other identified are toward have and We even the for working cohorts. the

So, our we I patient dosing to is quarter. can that’s expect do this at announce this point what that, first say

Geulah Livshits

And oncology you little the the that. and actually Then up a elaborate on regarding I you Can then, to company? collaboration programs. some more on what on Great. the have of work a drew Sandhill follow-up with follow questions bit that to

Charlie Albright

-- -- the technology allows a BINATE, call referred of NK the which a issue to was efficient significant which developed field. in is expansion has Sandhill as cells, they Sure. earlier,

a developing So a experience partner they technology of that NK developed that. that’s companies primary medicines as felt earlier It’s like good because field could has the driver and of there. the group in in we of part cell-based they the be

Geulah Livshits

cells delta to the NK applicable also or program? for primarily that gamma tech is the that And

Charlie Albright

run short that to applicable may be elements the gamma is that NK cells. are for in use the There delta primary

Geulah Livshits

a Gamida think with I you previously collaboration Cell. some at then And point had

technology. I NK around think

for Sandhill that both that’s is this Or still remind us, can donor-derived that? Or play do something to So, perceive collaboration a into you approaches come the active? is program?

Charlie Albright

Those MTA were independent an Yes. with collaborations, Cell. we Gamida and had

Operator

Silvan line with next Tuerkcan the our comes from And you. Thank question of Oppenheimer.

Your is now open. line

Silvan Tuerkcan

to and My first of we trial the color question. in ProQR quarter, of the it? or when What’s us How is year? Probably there across the could comparable on clinical congrats toward eventually can it taking would for for you data, some Well, LCAXX not comparable? Is patients? give end the what we my If question you not? just terms helpful? about Phase compare again thank X/X is similar it what’s be -- by get

Cindy Collins

So of to to I there the end some year on have data, done. potential to is anticipate that’s by do data that comment the the share

Our Charlie ProQR previous guidance, on to the I’ll of the comment question. portion ask

Charlie Albright

question. The I ballpark. the differences but to are patients wouldn’t in know if short there comparable, the not that’s are There your they’re answer huge is relatively differences. detailed same

Silvan Tuerkcan

for would Michelle, versus of the question us as understand how versus dimension role one view maybe D&S sickle And i.e., on in the on of you’re assets the Could how taking and different off risk CFO. now pay maybe of terms you Thanks. and the in, toward Great. maybe help allocate you oncology programs cell you them?

Michelle Robertson

at Sure. getting are I we publicly with Morgan talked feel comfortable partners. and on we we’ve that the JP I two have and but that at think the that about portfolio, the the speed of with our pillars programs the relationships

is assess a what to the that portfolio think whole. do as we’ll I continue

be think map prioritize can is the about as believe And timelines financing prioritization I sort we programs think events. investments that and in out our that supporting the So the portfolio, good next the to and in pipeline XX key to closely of such going we’re for that months and have our on to our we -- going I high-value with months a we have partners. focusing working programs, XX the because -- to the

Silvan Tuerkcan

you one indications What the here last AskBio, much. going you’re kind long-term? the on partnership. of in Thank are so that question And CNS this Great. maybe after

Cindy Collins

yet pursuing not disclosed have them. the indication that with We we’re

Operator

Yanan our Securities. [Operator Zhu of Fargo question line comes with you. Wells And Instructions] Thank from the next

now open. is line Your

Yanan Zhu

questions. taking Hi. the Thanks for

gained And So Or enhancer targeting just Would to anything approaches approach? point Thanks. is data also some promoter think gamma-globin hypothetically comparing targeted on if EDIT-XXX. share already? versus speaking, do HBF be maximum first the you question preclinical at BCLXXA your approach the induction approach achieves the combined? there two if gamma-globin you are promoter

Charlie Albright

first the when question be. an disclose data, comparative interesting point yes, I’m to that but is at answer will not is, sure we your Sure. question. The some will Combining them

-- you’d the challenges that be first wouldn’t I be is. had both are guess, at I you’d edit to some with come move with technical doing will editing there that. that. that time. There events do guess, some our challenges same to think I technical have

Yanan Zhu

Got Right. it.

same But are Just the there not any HBF than that mainly working understand two yes, and of proposal, is mechanisms a different the independent, -- has are other? maybe yes, that NK kinds also -- mentioned come pathways. you’re agree one to that the the this edits cell edits real on so you’re the persistence or pathway a something of -- the but inductions But equation? Would approach to as to -- Or increase they cell purpose persistence of question approach say, increase doing, see see it’s quick a better editing of the into is therefore, could I question in dosing perhaps I a potency program, be whether rather the achieved by that killing. in really mainly the multiple doesn’t you Thank kind think terms considering? do you. of NK and edit you’re to you

Charlie Albright

We make to as and increase even on dosing remains well. will edits multiple table the still persistence

Yanan Zhu

much. you Thank see. I very

Operator

remarks. And session. the this question-and-answer you. for I concludes turn CEO, Thank Collins call to back now to would today’s closing like Cindy

Cindy Collins

Great.

to to today’s medicines in evening. a and as we So thank bring for great call participating new patients. with for work Have that, we support, your you transformative

Operator

you this for and call. Thank today’s Ladies gentlemen, conference concludes participating.

You disconnect. may now

Editas Medicine (EDIT) 26 Feb 202019 Q4 Earnings call transcript